![Figure 1. Survival of patients with ATL stratified according to CCR4 mutations. (A) Five-year OS of all 116 patients with ATL was 46.2% (95% confidence interval [CI], 35.8%-56.6%). (B) Five-year OS of the 38 patients with CCR4 mutations and 78 patients without mutations was 40.0% (95% CI, 20.0%-60.0%) and 48.9% (95% CI, 36.4%-61.4%), respectively. (C) Five-year OS of the 16 patients with indolent variant and 100 patients with aggressive variant was 93.8% (95% CI, 81.8%-100.0%) and 38.0% (95% CI, 26.8%-49.2%), respectively. The former was significantly higher than the latter. (D) Among the patients with ATL with aggressive variant (n = 100), 5-year OS of those with CCR4 mutations (n = 35) or without (n = 65) was 38.5% (95% CI, 18.5%-58.5%) and 38.0% (95% CI, 24.5%-51.5%), respectively. (E) Among the 43 patients with ATL who did not receive any mogamulizumab-containing treatment or allogeneic hematopoietic stem-cell transplantation (HSCT), 5-year OS in the 13 with CCR4 mutations and 30 without was not reached and 51.4% (95% CI, 31.2%-71.6%), respectively. (F) Among the 31 patients with ATL who did receive allogeneic HSCT, 5-year survival from the day of allogeneic HSCT in the 14 patients with CCR4 mutations and 17 without was 42.9% (95% CI, 17.0%-68.8%) and 60.3% (95% CI, 35.6%-85.0%), respectively. (G) Among the 42 patients with ATL who received mogamulizumab-containing treatment but no allogeneic HSCT, 5-year survival from the day of the first dose of antibody in the 11 patients with CCR4 mutations and 31 without was 72.7% (95% CI, 46.4%-98.7%) and 26.2% (95% CI, 8.0%-44.4%), respectively. This difference reached statistical significance. (H) Among the 38 patients with ATL with aggressive variant who received mogamulizumab-containing treatment but no allogeneic HSCT, 5-year survival from the day of the first dose of antibody in the 10 patients with CCR4 mutations and 28 without was 80.0% (95% CI, 55.3%-100.0%) and 24.7% (95% CI, 6.3%-43.1%), respectively. This difference was also statistically significant. Survival curves were compared using the log-rank test, and the P value is indicated in each panel.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/132/7/10.1182_blood-2018-02-835991/4/blood835991f1.jpeg?Expires=1735496996&Signature=FS5-5em9ROT1CjE1147gaXkaKCD~ZV-tEsRruux46blU3InqnlIg5oWCTPSP4oSVeJl9CUHlToyHe7Rx~FUjk3VDeO5j4t0K9rkpkMbuR6ZqEIjAc5nCuV09JQ005SgCY5VaghRemEu-Zv1NaOkoFEk2C4ZZW-uRYtDjRG1EfawfeNqZMTGclFa98yaeDeW-Ih71wP9rQsXCeiW~YIfTYRqt96YblAwzWu4u-UCD3cxqySUjx-xqLE3jr-ubHg9ELUEyFAXWYBle3ClRBl-Tzv2FIV0U4jlKXBwm2ub-Fw-4bEwKaPn-6lhmoSRpCpA0GXiacTRUnfa5BuwG6QVWmg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Survival of patients with ATL stratified according to CCR4 mutations. (A) Five-year OS of all 116 patients with ATL was 46.2% (95% confidence interval [CI], 35.8%-56.6%). (B) Five-year OS of the 38 patients with CCR4 mutations and 78 patients without mutations was 40.0% (95% CI, 20.0%-60.0%) and 48.9% (95% CI, 36.4%-61.4%), respectively. (C) Five-year OS of the 16 patients with indolent variant and 100 patients with aggressive variant was 93.8% (95% CI, 81.8%-100.0%) and 38.0% (95% CI, 26.8%-49.2%), respectively. The former was significantly higher than the latter. (D) Among the patients with ATL with aggressive variant (n = 100), 5-year OS of those with CCR4 mutations (n = 35) or without (n = 65) was 38.5% (95% CI, 18.5%-58.5%) and 38.0% (95% CI, 24.5%-51.5%), respectively. (E) Among the 43 patients with ATL who did not receive any mogamulizumab-containing treatment or allogeneic hematopoietic stem-cell transplantation (HSCT), 5-year OS in the 13 with CCR4 mutations and 30 without was not reached and 51.4% (95% CI, 31.2%-71.6%), respectively. (F) Among the 31 patients with ATL who did receive allogeneic HSCT, 5-year survival from the day of allogeneic HSCT in the 14 patients with CCR4 mutations and 17 without was 42.9% (95% CI, 17.0%-68.8%) and 60.3% (95% CI, 35.6%-85.0%), respectively. (G) Among the 42 patients with ATL who received mogamulizumab-containing treatment but no allogeneic HSCT, 5-year survival from the day of the first dose of antibody in the 11 patients with CCR4 mutations and 31 without was 72.7% (95% CI, 46.4%-98.7%) and 26.2% (95% CI, 8.0%-44.4%), respectively. This difference reached statistical significance. (H) Among the 38 patients with ATL with aggressive variant who received mogamulizumab-containing treatment but no allogeneic HSCT, 5-year survival from the day of the first dose of antibody in the 10 patients with CCR4 mutations and 28 without was 80.0% (95% CI, 55.3%-100.0%) and 24.7% (95% CI, 6.3%-43.1%), respectively. This difference was also statistically significant. Survival curves were compared using the log-rank test, and the P value is indicated in each panel.
